Background: Despite the benefit of endocrine therapy, acquired resistance during or after treatment still remains a major challenge in estrogen receptor (ER)-positive breast cancer. We investigated the potential role of histone demethylase retinoblastoma-binding protein 2 (RBP2) in endocrine therapy resistance of breast cancer. Methods: Survival of breast cancer patients according to RBP2 expression was analyzed in three different breast cancer cohorts including METABRIC (n ¼ 1980) and KM plotter (n ¼ 1764). RBP2-mediated tamoxifen resistance was confirmed by in vitro sulforhodamine B (SRB) colorimetric, colony-forming assays, and in vivo xenograft models (n ¼ 8 per group). RNA-seq analysis and receptor tyrosine kinase assay were performed to identify the tamoxifen resistance mechanism by RBP2. All statistical tests were two-sided. Results: RBP2 was associated with poor prognosis to tamoxifen therapy in ER-positive breast cancer (P ¼ .04 in HYU cohort, P ¼ .02 in KM plotter, P ¼ .007 in METABRIC, log-rank test). Furthermore, RBP2 expression was elevated in patients with tamoxifen-resistant breast cancer (P ¼ .04, chi-square test). Knockdown of RBP2 conferred tamoxifen sensitivity, whereas overexpression of RBP2 induced tamoxifen resistance in vitro and in vivo (MCF7 xenograft: tamoxifen-treated control, mean [SD] tumor volume ¼ 70.8 [27.9] mm 
ER is the most important biomarker and therapeutic target in human breast cancer (19) . There are several distinct pathways leading to ER activation, such as estrogen-dependent/-independent, genomic, and nongenomic pathways (20, 21) . For targeting ER-positive (ERþ) breast cancer, ER signaling is inhibited via various routes, such as blocking estrogen biosynthesis, suppressing ER expression, or competing with estrogen (20) . Among endocrine agents, the anti-estrogen tamoxifen is the most widely used for ERþ breast cancer treatment (22) .
Despite the benefits, many patients undergo endocrine resistance via several mechanisms, including altered expression or activity of ER and the activation of receptor tyrosine kinases (RTKs) or other bypass signaling pathways (23) (24) (25) (26) (27) . In particular, ERþ breast cancer with acquired resistance to tamoxifen can use both estrogen and tamoxifen as the growth stimulus (28) (29) (30) , yet the mechanism for the agonist action of tamoxifen has not been fully established. Furthermore, long-term treatment with anti-estrogens develops new mechanisms of resistance that are distinct from resistance mechanisms that occur by short-term treatment (30, 31) , implying the complexity of endocrine therapy resistance.
In this study, we explored the potential oncogenic role of RBP2 in ER-positive breast cancer to identify the novel molecular mechanism of tamoxifen resistance in breast cancer.
Methods

Patients and Surgical Specimens
Patients with invasive ductal carcinoma (n ¼ 200) who successfully underwent surgery at Hanyang University Hospital (Seoul, Republic of Korea) between 2000 and 2009 were enrolled under the approval of the Institutional Review Boards of Hanyang University. Informed consent was provided by all patients enrolled in the study. Histopathological and clinical data were obtained from pathology reports and medical records. Tissue microarray construction was assessed as described previously (32) . For survival analysis, breast cancer patients were stratified by the RBP2 level, defined by immunohistochemistry (Supplementary Methods, available online).
Survival Analysis Using Public Data
Using the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (33) and Kaplan-Meier plotter (KM plotter, http://kmplot.com), the association between RBP2 expression level and disease-free survival (DFS) in human breast cancer was analyzed. Patients were stratified according to RBP2 mRNA expression (METABRIC, median; KM plotter, lower quartile). Further details are available in the Supplementary Methods (available online).
Sulforhodamine B Colorimetric Assay
The in vitro toxicology assay kit (Sulforhodamine B based, TOX 6) was purchased from Sigma-Aldrich (St Louis, MO). Cells (5 Â 10 3 cells/ well) were cultured in phenol red-free DMEM containing 10% fetal bovine serum in a 96-well plate and supplemented with 4-hyrdoxytamoxifen for five days. The cells were fixed in trichloroacetic acid (TCA) for one hour at 4 C and stained with 0.4% sulforhodamine B for 30 minutes. The stained cells were destained with 1% acetic acid and dissolved in 10 mM Tris for OD determination at 490 nm.
Immunoblotting and Co-immunoprecipitation Assays
Cells were lysed in radioimmunoprecipitation assay buffer supplemented with protease and phosphatase inhibitors.
Immunoblotting and co-immunoprecipiation (IP) assays were then performed using appropriate antibodies as described previously (32) . Further details are available in the Supplementary Methods (available online).
Chromatin Immunoprecipitation Assay
Chormatin immunopreceipitation (ChIP) was performed using a ChIP assay kit according to the manufacturer's instructions (Upstate Biotechnology, Lake Placid, NY 
Phospho-RTK Array
The Human Phospho-RTK array Kit was purchased from R&D systems (Minneapolis, MN). Diluted cell lysates were incubated with human phosphokinase array membranes, and bound phosphoproteins were analyzed according to the manufacturer's instructions. Each membrane contained kinase-specific antibodies spotted in duplicate.
Orthotopic Xenograft
All mouse experiments were approved by the Hanyang University Animal Care and Use Committee (Seoul, Republic of Korea). Five-week-old female NOD/SCID mice were purchased from KOATECH (Pyeongtaek, Republic of Korea). MCF7 and BT474 cells (4 Â 10 6 and 2 Â 10 6 cells, respectively) mixed with Matrigel (BD bioscience, San Jose, CA) were injected into the mammary fat pads of mice implanted with E2 pellets (0.72 mg/ pellet; 60-day release) before one week. After one week, the mice received a subcutaneous injection of tamoxifen pellet (5 mg/pellet; 60-day release), as described previously (34) . Tumor growth was monitored twice per week, and the tumor volume was calculated as 1/2 Â (long diameter) Â (short diameter) 2 .
Statistics
The statistical significance of differences between two groups was analyzed with the unpaired Student's t test using SPSS (version 12.0; SPSS, Inc., Chicago, IL). For multiple group comparisons and repeated measures, analysis of variance (ANOVA) and repeated-measures ANOVA (RM ANOVA), followed by post hoc least significant difference (LSD) test, were used. All P values were two-sided. P values of less than .05 were considered statistically significant. , and outlier points. The P value was calculated using the two-sided Student's t test. A table shows the association between RBP2 expression and tumor recurrence after tamoxifen therapy (lower right panel). Statistical significance was assessed protein was associated with worse DFS in all cases and ERþ breast cancer (n ¼ 200 and 141, log-rank P ¼ .05 in both cases) ( Figure 1A ; Supplementary Figure 1A , available online), as well as in patients who received tamoxifen therapy (n ¼ 85, logrank P ¼ .04) ( Figure 1A Figure 1 , B-E, available online). Consistent with the clinical evidence, RBP2 overexpression induced tamoxifen resistance in MCF7 cells with tamoxifen sensitivity and low RBP2 expression (P < .001, RM ANOVA) ( 
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Functional Role of RBP2 in ER-Dependent Transcriptional Activation
We next investigated the molecular mechanism underlying tamoxifen resistance by RBP2 based on RNA sequencing (RNAseq). In RBP2-overexpressing MCF7 cells, approximately 60% of the RBP2 target genes overlapped with ER-bound and/or tamoxifen resistance-associated genes ( Figure 3A ; Supplementary Table 3 , available online). Gene set enrichment analysis (GSEA) also showed that RBP2-target genes were linked to the estradiol response and tamoxifen resistance pathways (false discovery rate-adjusted P < .001) ( Figure 3B ; Supplementary Figure 3A and Supplementary Table 4 , available online). These gene sets included several well-known ER-target genes, such as NRIP1, CCND1, IGFBP4, and IGFBP5, which are known to be associated with tamoxifen resistance or to have clinical significance in ERþ breast cancer (36) (37) (38) (39) . The altered expression levels of these genes were validated by quantitative reverse-transcription PCR (qRT-PCR) ( Figure 3C ). We further verified the RBP2 effect on ER-dependent transcription. In RBP2-overexpressing MCF7 cells, estrogen response element (ERE) luciferase activity was stimulated in response to 17b-estradiol (E2) and/or 4-hydroxytamoxifen treatment (P < .001 for vehicle vs E2, vehicle vs 4-hydroxytamoxifen) (Supplementary Figure 3B , available online). The expression levels of tamoxifen resistance-associated ER-target genes, including NRIP1 and CCND1, were subsequently upregulated under these conditions ( Figure 3D ; Supplementary Figure 3C , available online). Similarly, RBP2 knockdown recovered the inhibitory effect of tamoxifen on ER-dependent transcription in MCF7-TamR and BT474 cells (ERE-luc: P < .001 for E2 vs 4-hydroxytamoxifen, in both cells) ( Figure 3D ; Supplementary Figure 3D , available online). This E2 agonist action of tamoxifen by RBP2 was retained in RBP2 H483A-mutant-expressing cells (Supplementary Figure 3B , available online), implying that RBP enhanced ER-dependent transcription regardless of its demethylase activity. In MCF7 cells, RBP2 overexpression increased the RBP2 interaction with ER and histone acetyltransferase (HAT) p300 in response to E2 and/or 4-hydroxytamoxifen treatment ( Figure 3E ). Furthermore, RBP2-ER-p300 directly bound to the promoter regions of NRIP1 and CCND1, which contain RBP2-binding motifs 'CCGCCC' (40) and EREs, and induced histone H3 acetylation (H3ac) in this region (all P < .001) ( Figure 3F ; Supplementary Figure 3E , available online). These findings suggested that RBP2 switches tamoxifen function from an E2 antagonist to an E2 agonist by sustaining RBP2-ER-p300 complex in the regions of ER-dependent transcriptional activation ( Figure 3G ).
RBP2-ER-NRIP1 Complex-Mediated Gene Silencing of IGFBP4/5
Because RBP2 was also involved in the transcriptional repression of ER target genes, including IGFBP4 and IGFBP5 ( Figure 3 , A and C; Supplementary Figure 3C and Supplementary Table 3 , available online), we next investigated the molecular mechanism by which RBP2 suppresses ER-dependent transcription. Nuclear receptor interacting protein 1 (NRIP1) has been known as a major ER corepressor (41) and also was involved in histone deacetylase (HDAC)-mediated gene silencing (42, 43) , raising the possibility of cooperation between RBP2 and NRIP1 in the regulation of ER-dependent transcriptional repression. Indeed, the increase in NRIP1 expression in response to RBP2 facilitated the interaction between RBP2, ER, NRIP1, and HDAC1 ( Figure 4A ). Unlike NRIP1 and Cyclin D1, regulation of IGFBP4 and IGFBP5 by RBP2 was dependent on its demethylase activity (control vs RBP2, P < .001 for IGFBP4, P ¼ .006 for IGFBP5; RBP2 vs RBP2 H483A , P ¼ .001 for both genes) ( Figure 4B; Supplementary Figure 4 , available online). Consistently, RBP2-ER-NRIP1-HDAC1 complex was recruited to the promoter regions of IGFBP4 and IGFBP5 containing both RBP2-and ER-binding sites, thus repressing H3K4me2/me3 and H3ac (all P < .001) ( Figure 4C ). The RBP2 H483A mutant recovered H3K4me2/3 and H3ac in their promoter regions ( Figure 4D ).
Insulin-like growth factor binding proteins (IGFBPs) block insulin-like growth factor-1 receptor (IGF1R) activation by disrupting ligand binding to IGF1R (44) . Indeed, the reduced IGFBP4 and IGFBP5 expression in response to RBP2 increased IGF1R phosphorylation and activated the downstream PI3K/AKT pathway ( Figure 4E) . Interestingly, the enhanced IGF1R activity was ARTICLE completely inhibited, whereas AKT was incompletely dephosphorylated by expression of the RBP2 H483A, suggesting that RBP2-mediated AKT activation partially depends on IGF1R signaling and RBP2 catalytic activity. Together, these findings indicated that RBP2 activates IGF1R signaling via the suppression of IGFBP4 and IGFBP5 transcription by collaborating with ER-NRIP1-HDAC1 in a histone demethylation-dependent manner ( Figure 4F ).
RBP2 Effect on IGF1R/EGFR/HER2 Signaling in Mediating Tamoxifen Resistance
To further define the mechanism responsible for the regulatory effect of RBP2 on the PI3K/AKT pathway, changes in the activities of multiple receptor tyrosine kinases (RTKs) following RBP2 overexpression were analyzed. Not only the IGF1R but also ErbB family receptors were remarkably activated by RBP2 Relative mRNA levels CCND1 P < .001 P < .001 P < .001 P < .001 P < .001 P < .001
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Relative mRNA levels NRIP1 P < .001 P < .001 P < .001 P < .001 P < .001 P < .001 P < .001 Figure 6B , available online). These data suggested that RBP2 activates ErbB signaling through the stabilization of EGFR and HER2 proteins in a demethylase activityindependent manner. Previous studies have demonstrated that crosstalk between the IGF1R and the ErbB family activates downstream signaling pathways (45, 46) . In BT474 cells, which have elevated levels of the IGF1R and ErbB family, the interaction between IGF1R, EGFR, and HER2 was inhibited by RBP2 knockdown (Figure 5F ), raising the possibility that RBP2 may activate PI3K/AKT signaling by facilitating the crosstalk between IGF1R and EGFR/HER2. Hyperactivation of the PI3K/AKT pathway has been considered a possible mechanism leading to endocrine therapy resistance in ERþ breast cancer (47) . RBP2-overexpressing MCF7 cells were sensitized to the PI3K inhibitor BKM120, but not tamoxifen (% cell viability [SD] , BKM120 ¼ 67.1 [2.7] %, tamoxifen ¼ 89.0 [3.8]%, P < .001) ( Figure 5H ). Moreover, tamoxifen resistance by RBP2 was recovered by combination treatment with tamoxifen and BKM120 (% cell viability [SD] , tamoxifen þ BKM120 ¼ 41.3 [5.6]%, P < .001). Collectively, these findings implied that RBP2-induced tamoxifen resistance is due to activation of the PI3K/AKT pathway via the IGF1R and ErbB signaling.
Discussion
Here, we demonstrated the functional role of RBP2 in mediating ER activity and tamoxifen resistance in breast cancer. RBP2 regulated both ER-dependent transcriptional activation and repression in collaboration with ER-p300 and ER-NRIP1-HDAC1, respectively ( Figure 6A ). The decreased expression of IGFBP4/5 by RBP2-ER-NRIP1-HDAC1 resulted in IGF1R activation. RBP also promoted the crosstalk between IGF1R and ErbB receptors by enhancing the EGFR and HER2 protein stability, resulting in activation of the PI3K/AKT pathway and tamoxifen resistance ( Figure 6B ). This evidence suggests RBP2 as a crucial molecular target for tamoxifen-resistant ERþ breast cancer.
Recent studies have suggested an oncogenic role of RBP2 in breast cancer. RBP2 knockout in MMTV-neu mice abrogated tumorigenesis and metastatic potential (14) . In human breast tumor, amplified and overexpressed RBP2 was associated with increased cell proliferation and resistance to erlotinib (11) . Combinational treatment with an RBP2 inhibitor and herceptin or gefitinib repressed colony formation in HER2þ breast cancer cells (18) . To our knowledge, this study provides the first evidence of oncogenic RBP2 function in hormone-dependent breast cancer as a key regulator of ER and RTK signaling. Due to the innate and acquired resistance to endocrine therapy via the activation of ER, RTKs, and other bypass tracks, various studies have proposed combination treatment with endocrine therapy and targeted drugs for RTK signaling, such as ErbB and IGF1R inhibitors, and PI3K-AKT inhibitors (47) (48) (49) (50) (51) . We also observed that combination treatment with tamoxifen and PI3K inhibitor BKM120 was effective for RBP2-overexpressing ERþ breast cancer cells with tamoxifen resistance. These findings suggest that ERþ breast cancers with high expression of RBP2 may be required for combined treatment with tamoxifen and other 
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targeted drugs, such as a PI3K/AKT blocker, related to RBP2-dependent pathways. Collectively, RBP2 might serve as a new prognostic marker and therapeutic target in ERþ breast cancer.
Notably, RBP2 activates not only E2-bound ER but also tamoxifen-bound ER to allow ER-dependent transcriptional regulation, leading to tamoxifen resistance. Abnormal activity of ER coregulators contributes to the development of breast cancer and the induction of endocrine resistance. For example, the upregulation of co-activators, including NCOA1/p300 complex and AIB1, is associated with the E2 agonist function of tamoxifen via ER activation and ErbB family overexpression (52) (53) (54) (55) . Consistently, high levels of corepressors, such as NRIP1, FOXA1, and DNMT1, induce tamoxifen resistance (38, 56, 57) . Here, we verified that RBP2 induces consistent ER and p300 binding to the NRIP1 and CCND1 promoter regions, thus upregulating their expression in both E2-and tamoxifen treatment conditions, suggesting that RBP2 may block the antagonist function of tamoxifen-bound ER via sustaining the interaction with ER coactivators in the transcriptionally active ER-bound regions. In addition, NRIP1 upregulation appears to change the RBP2-containing transcriptional active complex to a transcriptional repressive complex. Although NRIP1 was initially identified as a co-activator of ER (58), a recent study demonstrated that NRIP1 expression is promptly induced in response to estrogen and subsequently mediates ER-dependent transcriptional repression (41) . Based on our findings regarding RBP2/ER/NRIP1/ HDAC1-mediated epigenetic repression of IGFBP4/5, increased NRIP1 by RBP2 may be crucial for a formation of RBP2/ERcontaining transcriptional repressive complex. Collectively, RBP2 acts as both a co-activator and a corepressor of ER and alters tamoxifen-bound ER activity to regulate tamoxifen resistance-associated gene transcription.
Accumulating studies have identified the demethylase activity-dependent oncogenic function of RBP2 (10, 12, 15) . For example, RBP2 removes H3K4 methylation from p27 promoters, thus inducing tumorigenesis and metastasis (12) . The reduction in global levels of H3K4 methylation that requires RBP2 is associated with gefitinib resistance in lung cancer (15) . A recent study reported that the PI3K/AKT pathway inhibits RBP2-mediated H3K4 demethylation by phosphorylating RBP2 protein in breast cancer progression (59) . However, another study demonstrated that RBP2 promotes breast cancer progression and metastasis via the histone demethylation-independent regulation of genes related to invasion, although the molecular mechanism remains unclear (14) . We suggest that RBP2 have both demethylation-dependent and -independent functions in oncogenic processes. In the regulation of ER-dependent transcription, RBP2/ER/NRIP1/HDAC1 repressive complex was dependent on a demethylase activity, while RBP2 cooperated with ER and p300 in a histone demethylase activity-independent manner. Thus, the association between RBP2, ER, and ER-dependent coregulators might be very important to determine RBP2-mediated transcriptional activation or repression and its dependence on catalytic activity. Furthermore, RBP2 stabilized EGFR and HER2 proteins independently of its demethylase activity. Together, our findings suggest that RBP2 is closely linked to multiple transcriptional-and post-translational regulatory mechanisms to promote breast progression in a demethylationdependent or demethylation-independent manner.
A limitation of this study is that there is still no way to test the pharmacological effect of RBP2 inhibition on tamoxifenresistant breast cancer. Currently available RBP2 inhibitors are not specific to RBP2 and only target the demethylase activity of RBP2, even though both histone demethylation-dependent and -independent function of RBP2 are crucial for tamoxifen resistance. The development of novel selective inhibitors for a broad spectrum of RBP2 function and further preclinical and clinical studies using the inhibitors will be needed for therapeutically targeting RBP2 in tamoxifen-resistant breast cancer.
In conclusion, we demonstrated that RBP2 is crucial for tamoxifen resistance by altering ER-dependent transcription with ER coregulators and enhancing the IGF1R/EGFR/HER2 signaling pathway in various transcriptional and post-transcriptional regulatory mechanisms. Thus, RBP2 may be a prospective prognostic marker and therapeutic target in breast cancer, particularly in tamoxifen-resistant ERþ breast cancer. 
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